A Phase 3 interventional study of Semaglutide and Placebo in Overweight and Obesity, sponsored by Novo Nordisk A/S. Recruiting at 62 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.
Among the 143 studies testing semaglutide in Obesity, this one is the 19th largest by planned enrollment, is one of 30 that started in 2026, is one of 42 in phase 3, reaches primary completion later than 50 of the 76 other live ones, and was the 134th registered.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
Browse Obesity studies →68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Alain Dagher · Sites in Canada
Children's Hospital Medical Center, Cincinnati · Sites in United States
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Yale University · Sites in United States
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 168 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 24 · Phase 3 46 · Phase 4 40
First in 2014; this study’s year is marked. 30 started in 2026.
This study's planned enrollment of 450 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Median enrollment 100 across the 143 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 143 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,404 studies on the registry; 101 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 100 (49%) have results posted.
205 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 136 finished, 38 (28%) have results posted.
Among the 205 studies in Obesity by Novo Nordisk A/S, this one is the 35th largest by planned enrollment of the 164 interventional ones that give a count, is one of 47 that started in 2026, is one of 62 in phase 3, reaches primary completion later than 35 of the 65 other live ones, and was the 195th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Among the 143 studies testing semaglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 205 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 450 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,404 studies on the registry; 101 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 100 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(BMI) of
≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease.
OR
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive two different oral doses of semaglutide as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: Semaglutide
Participants will receive oral dose of placebo as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: Placebo
Participants will receive semaglutide orally.
Participants will receive placebo orally.
Relative change in body weight
Measured as percentage change in body weight.
Time frame: From baseline (week 0) to week 60
Achievement of body weight reduction greater than or equal to (≥) 5 percentage (%) (Yes/No)
Measured as count of participant.
Time frame: At week 60
Achievement of body weight reduction ≥ 10% (Yes/No)
Measured as count of participant.
Time frame: At week 60
Achievement of body weight reduction ≥ 15% (Yes/No)
Measured as count of participant.
Time frame: At week 60
Change in waist circumference
Measured as centimeter (cm).
Time frame: From baseline (week 0) to week 60
Change in body weight
Measured as kilogram (kg).
Time frame: From baseline (week 0) to week 60
Change in high sensitivity C-Reactive Protein (hsCRP)
Measured as milligrams per deciliter (mg/dL).
Time frame: From baseline (week 0) to week 60
Change in systolic blood pressure
Measured as millimetres of mercury (mmHg).
Time frame: From baseline (week 0) to week 60
Change in diastolic blood pressure
Measured as (mmHg).
Time frame: From baseline (week 0) to week 60
Change in fasting plasma glucose (FPG)
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 60
Change in glycated haemoglobin (HbA1c)
Measured as %-point.
Time frame: From baseline (week 0) to week 60
Change in glycaemic status
Measured as count of participants.
Time frame: From baseline (week 0) to week 60
Change in lipids: Total cholesterol
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 60
Change in lipids: High density lipoprotein (HDL) cholesterol
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 60
Change in lipids: Non-HDL cholesterol
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 60
Change in lipids: Low density lipoprotein (LDL) cholesterol
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 60
Change in lipids: Very low density lipoprotein (VLDL) cholesterol
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 60
Change in lipids: Triglycerides
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 60
Change in lipids: Free fatty acids
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 60
Change in waist-height ratio (WtHR)
Measured as change in waist-height ratio.
Time frame: From baseline (week 0) to week 60
Number of treatment emergent adverse events
Measured as count of events.
Time frame: From baseline (week 0) to week 67
Number of treatment emergent serious adverse events
Measured as count of events.
Time frame: From baseline (week 0) to week 67
Number of treatment emergent adverse events leading to permanent treatment discontinuation
Measured as count of events.
Time frame: From baseline (week 0) to week 67
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Feb 2028, 18 months after the start.
Of 198 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 18 months is below that.
Counting every sponsor, half of 261 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide